A Phase 1 interventional study of BNT331 and Placebo in Bacterial Vaginosis, sponsored by BioNTech SE. Completed at 6 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by BioNTech SE · Phase 1, Interventional, and Treatment
Part A: Placebo (Combined for Cohorts 1, 2 and 3) · Part A: Cohort 1: BNT331 2 Milligram (mg) · Part A: Cohort 2: BNT331 5 mg · Part A: Cohort 3: BNT331 20 mg · Part B: Placebo (Combined for Cohorts 4 and 5) · Part B: Cohort 4: BNT331 5 mg · Part B: Cohort 5: BNT331 20 mg
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Vaginosis, Bacterial with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Vaginosis, Bacterial · United States.
Among the 82 studies in Vaginosis, Bacterial with a site in United States, this one is the 31st largest by enrollment of the 69 interventional ones that give a count, is one of 8 that started in 2024, is one of 12 in phase 1, and was the 74th registered.
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
Browse Vaginosis, Bacterial studies →8 of the 82 studies in Vaginosis, Bacterial with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
Tulane University · Sites in United States
Ages 18+ · Healthy volunteers
Cern Corporation · Sites in United States
Ages 18+ · Women only
Queen's Medical Center · Sites in United States
Ages 18–54 · Women only · Healthy volunteers
Douglas Kwon · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 19 · Phase 3 14 · Phase 4 10
First in 1999; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is close to the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Median enrollment 81 across the 69 interventional studies, 519 across the 13 observational. Of the 66 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 82 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 77 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
BioNTech SE has 1 study filed under Vaginosis, Bacterial — fewer than ten, so there is no comparison to draw.
5 of the studies in Vaginosis, Bacterial with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT05753813Queen's Medical CenterExploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome | 2027-01-30 |
| NCT04046900Douglas KwonVaginal Microbiota Transplant | 2027-01-30 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT01829204Texas Tech University Health Sciences CenterProspective Data Bank Creation to Study Vaginal Conditions | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Vaginosis, Bacterial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).
Part A included single ascending dose levels and assessed the safety of BNT331 and described the incidence of adverse events (AEs) for participants randomized at a ratio of 3:1 to BNT331 or placebo. Participants received one single dose of study treatment.
Part B included multiple ascending dose levels. Participants were randomized at a ratio of 2:1 to BNT331 or placebo. Participants with BV received study treatment for five consecutive days.
The vaginal inserts were self-administered by the participant. The participants received detailed instructions from the investigator on how to self-administer the vaginal inserts at home.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Inclusion Criteria (applicable to all participants unless otherwise specified):
Not menstruating or having vaginal bleeding:
Part A only: Were healthy according to screening procedures. Part B only: Participants suffering from BV but who were otherwise healthy in the clinical judgement of the investigator.
The participant must have been on the same form of highly effective for at least 3 months prior to dosing (Visit 1) and must agree to keep this method until:
Women of childbearing potential who agree not to donate or cryopreserve eggs (ova, oocytes) for the purposes of assisted reproduction during study:
Agree to abstain from vaginal intercourse:
Agree to not use any vaginal products, e.g., creams, gels, foams, sponges, douches, and tampons (except during menstruation):
Part B only: Have a clinical diagnosis of BV, defined as having all the following Amsel's criteria (4/4):
Exclusion Criteria (applicable to all participants unless otherwise specified):
Pregnant, lactating, or planning to become pregnant during their study participation and for at least:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants received a single dose of placebo administered as a vaginal insert on Day 1.
Other: Placebo
Healthy participants received a single 2 mg dose of BNT331 administered as a vaginal insert on Day 1.
Drug: BNT331
Healthy participants received a single 5 mg dose of BNT331 administered as a vaginal insert on Day 1.
Drug: BNT331
Healthy participants received a single 20 mg dose of BNT331 administered as a vaginal insert on Day 1.
Drug: BNT331
Participants diagnosed with bacterial vaginosis received placebo as a vaginal insert once daily for five consecutive days.
Other: Placebo
.Participants diagnosed with bacterial vaginosis received 5 mg dose of BNT331 as a vaginal insert once daily for five consecutive days.
Drug: BNT331
Participants diagnosed with bacterial vaginosis received 20 mg dose of BNT331 as a vaginal insert once daily for five consecutive days.
Drug: BNT331
Vaginal insert
Vaginal insert
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE
Treatment-emergent adverse events (TEAEs) are those Adverse Events with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition.
Time frame: Up to 7 days post dose on Day 1
Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAE
Treatment-emergent adverse events are those AEs with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AE were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE.
Time frame: Up to 120 days after first dose on Day 1
Part A: Serum Concentrations of BNT331 Active Substance
Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and geometric coefficient of variation (GCV) data were reported for the outcome measure.
Time frame: Pre-dose, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours and 7 days post-dose on Day 1
Part B: Serum Concentrations of BNT331 Active Substance
Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and coefficient of variation data were reported for the outcome measure.
Time frame: Pre-dose, At Visit 2 (i.e. Day 6 post dose on Day 1) and at Visit 3 (i.e., Days 21 to 30 post-dose on Day 1)
Part A: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood
ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADA for BNT331 active substance in blood were reported in the outcome measure.
Time frame: At Pre-dose (Baseline), at 7 days post-dose on Day 1
Part B: Number of Participants With Qualitative Anti-drug Antibody (ADA) for BNT331 Active Substance in Blood
ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADAs for BNT331 active substance in blood were reported in the outcome measure.
Time frame: At Pre-dose (Baseline), 6 days after the first dose on Day 1, 21 to 30 days after the first dose on Day 1, and 60 days after the first dose on Day 1
Part B - Number of Participants With Clinical Cure
Clinical cure was defined as normalization of the vaginal discharge, a negative KOH "Whiff" test, and clue cells \<20% of the total epithelial cells/high power field on microscopic examination of the vaginal fluid. Data for this outcome measure was not planned to be collected and analyzed for Part A.
Time frame: At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
Part B: Number of Participants With Nugent Score Cure/Microbiological Cure
Nugent score cure/Microbiological cure was defined as a score of \<4. A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.
Time frame: At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
Part B: Number of Participants (Responders Outcome) Reporting Clinical Cure With a Normal Nugent Score of Less Than (<) 4
Responder outcome was defined as an occurrence of clinical cure with a normal Nugent score (\<4). A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.
Time frame: At 6 days after first dose on Day 1; and 21 to 30 days after the first dose on Day 1
| Milestone | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 26 | 26 | 26 |
| Safety analysis set | 6 | 6 | 6 | 6 | 25 | 25 | 23 |
| Completed | 6 | 6 | 6 | 6 | 20 | 24 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 6 | 2 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Other-unspecified | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Treatment-emergent adverse events (TEAEs) are those Adverse Events with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition.
| Participants | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg |
|---|---|---|---|---|
| Any TEAE | 2 | 1 | 1 | 2 |
| Any serious TEAE | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events are those AEs with an onset on or after the date and time of study treatment or events which were present before treatment, and which worsened after treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect or was another medically important condition. AE were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE.
| Participants | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|---|
| Any TEAE | 9 | 8 | 7 |
| Any serious TEAE | 0 | 0 | 0 |
Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and geometric coefficient of variation (GCV) data were reported for the outcome measure.
| nanograms per milliliter | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg |
|---|---|---|---|
| Predose | NA ± NA | NA ± NA | NA ± NA |
| 1 hour Post dose | NA ± NA | NA ± NA | NA ± NA |
| 2 hour Post dose | NA ± NA | NA ± NA | NA ± NA |
| 4 hour Post dose | NA ± NA | NA ± NA | NA ± NA |
| 6 hour Post dose | NA ± NA | NA ± NA | NA ± NA |
| 24 hour Post dose | NA ± NA | NA ± NA | NA ± NA |
| 7 days Post dose | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected to determine the serum concentrations of BNT331 active substance. Geometric Mean and coefficient of variation data were reported for the outcome measure.
| nanograms per milliliter | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|
| Pre-dose | NA ± NA | NA ± NA |
| Visit 2 | NA ± NA | NA ± NA |
| Visit 3 | NA ± NA | NA ± NA |
ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADA for BNT331 active substance in blood were reported in the outcome measure.
| Participants | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg |
|---|---|---|---|
| At Pre-dose (Baseline) | 0 | 0 | 0 |
| At 7 days post-dose on Day 1 | 0 | 0 | 0 |
ADA-positive samples were defined as a sample confirmed to be positive for the presence of reactive antibodies. Positive qualitative ADAs for BNT331 active substance in blood were reported in the outcome measure.
| Participants | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|
| At Pre-dose (Baseline) | 0 | 0 |
| 6 days after the first dose on Day 1 | 0 | 0 |
| 21 to 30 days after the first dose on Day 1 | 0 | 0 |
| 60 days after the first dose on Day 1 | 2 | 0 |
Clinical cure was defined as normalization of the vaginal discharge, a negative KOH "Whiff" test, and clue cells \<20% of the total epithelial cells/high power field on microscopic examination of the vaginal fluid. Data for this outcome measure was not planned to be collected and analyzed for Part A.
| Participants | Part B: Placebo | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|---|
| At 6 days after first dose on Day 1 | 9 | 7 | 13 |
| 21 to 30 days after the first dose on Day 1 | 7 | 7 | 11 |
Nugent score cure/Microbiological cure was defined as a score of \<4. A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.
| Participants | Part B: Placebo | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|---|
| At 6 days after first dose on Day 1 | 3 | 3 | 3 |
| 21 to 30 days after the first dose on Day 1 | 2 | 1 | 1 |
Responder outcome was defined as an occurrence of clinical cure with a normal Nugent score (\<4). A Nugent score of 7-10 is indicative of BV, while a score of 4 to 6 is considered intermediate vaginal microbiota and a score of 0 to 3 is considered normal vaginal microbiota. Data for this outcome measure was not planned to be collected and analyzed for Part A.
| Participants | Part B: Placebo | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|---|
| At 6 days after first dose on Day 1 | 1 | 3 | 3 |
| 21 to 30 days after the first dose on Day 1 | 1 | 1 | 1 |
Collected over AE and SAE data were collected up to 7 days post dose on Day 1 for Part A and up to 120 days after first dose on Day 1 for Part B arms. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo (Combined for Cohorts 1, 2 and 3) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A: Cohort 1: BNT331 2 Milligram (mg) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A: Cohort 2: BNT331 5 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A: Cohort 3: BNT331 20 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part B: Placebo (Combined for Cohorts 4 and 5) | 0/25 (0%) | 0/25 (0%) | 9/25 (36%) |
| Part B: Cohort 4: BNT331 5 mg | 0/25 (0%) | 0/25 (0%) | 8/25 (32%) |
| Part B: Cohort 5: BNT331 20 mg | 0/23 (0%) | 0/23 (0%) | 7/23 (30.4%) |
| Event | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg |
|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/25 | 0/25 | 0/23 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/25 | 0/25 | 0/23 |
| NauseaGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/25 | 0/25 | 0/23 |
| VomitingGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/25 | 0/25 | 0/23 |
| Traumatic painInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 1/6 | 0/25 | 0/25 | 0/23 |
| HeadacheNervous system disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/25 | 0/25 | 1/23 |
| Micturition urgencyRenal and urinary disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/25 | 0/25 | 0/23 |
| Vulvovaginal painReproductive system and breast disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/25 | 0/25 | 0/23 |
| Vulvovaginal mycotic infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 3/25 | 2/25 | 1/23 |
| Abdominal pain lowerGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/25 | 2/25 | 0/23 |
| Age, Continuous(Years) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A | 35.7 ± 7.61 | 36.3 ± 10.82 | 36.8 ± 8.42 | 31.8 ± 7.78 | — | — | — | 35.2 ± 8.41 |
| Part B | — | — | — | — | 35.2 ± 8.02 | 34.4 ± 9.00 | 36.0 ± 8.29 | 35.1 ± 8.36 |
| Sex: Female, Male(Participants) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A — Female | 6 | 6 | 6 | 6 | — | — | — | 24 |
| Part A — Male | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part B — Female | — | — | — | — | 25 | 25 | 23 | 73 |
| Part B — Male | — | — | — | — | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A — Hispanic or Latino | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part A — Not Hispanic or Latino | 6 | 6 | 6 | 6 | — | — | — | 24 |
| Part A — Unknown or Not Reported | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part B — Hispanic or Latino | — | — | — | — | 1 | 2 | 2 | 5 |
| Part B — Not Hispanic or Latino | — | — | — | — | 24 | 23 | 21 | 68 |
| Part B — Unknown or Not Reported | — | — | — | — | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A — American Indian or Alaska Native | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part A — Asian | 1 | 0 | 1 | 0 | — | — | — | 2 |
| Part A — Black or African American | 1 | 0 | 0 | 0 | — | — | — | 1 |
| Part A — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part A — White | 4 | 5 | 5 | 5 | — | — | — | 19 |
| Part A — Multiple | 0 | 0 | 0 | 1 | — | — | — | 1 |
| Part A — Other | 0 | 1 | 0 | 0 | — | — | — | 1 |
| Part A — Not reported | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part A — Unknown | 0 | 0 | 0 | 0 | — | — | — | 0 |
| Part B — American Indian or Alaska Native | — | — | — | — | 0 | 0 | 0 | 0 |
| Part B — Asian | — | — | — | — | 0 | 0 | 0 | 0 |
| Part B — Black or African American | — | — | — | — | 19 | 19 | 17 | 55 |
| Part B — Native Hawaiian or Other Pacific Islander | — | — | — | — | 0 | 0 | 0 | 0 |
| Part B — White | — | — | — | — | 5 | 4 | 6 | 15 |
| Part B — Multiple | — | — | — | — | 1 | 1 | 0 | 2 |
| Part B — Other | — | — | — | — | 0 | 1 | 0 | 1 |
| Part B — Not reported | — | — | — | — | 0 | 0 | 0 | 0 |
| Part B — Unknown | — | — | — | — | 0 | 0 | 0 | 0 |
| Anti-drug Antibody (ADA) in Blood Results Positive(Participants) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A | — | 0 | 0 | 0 | — | — | — | 0 |
| Part B | — | — | — | — | — | 0 | 0 | 0 |
| Nugent Score(Score on a scale) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A | 0.8 ± 2.04 | 0.0 ± 0.00 | 0.5 ± 1.22 | 0.0 ± 0.00 | — | — | — | 0.3 ± 1.17 |
| Part B | — | — | — | — | 7.6 ± 3.44 | 6.6 ± 3.59 | 8.4 ± 2.61 | 7.5 ± 3.30 |
| Amsel's Criteria(Participants) | Part A: Placebo (Combined for Cohorts 1, 2 and 3) | Part A: Cohort 1: BNT331 2 Milligram (mg) | Part A: Cohort 2: BNT331 5 mg | Part A: Cohort 3: BNT331 20 mg | Part B: Placebo (Combined for Cohorts 4 and 5) | Part B: Cohort 4: BNT331 5 mg | Part B: Cohort 5: BNT331 20 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Part A | — | — | — | — | — | — | — | 0 |
| Part B | — | — | — | — | 25 | 25 | 23 | 73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2024 to primary completion in Jul 2025, 12 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
Part A: Placebo (Combined for Cohorts 1, 2 and 3) · Part A: Cohort 1: BNT331 2 Milligram (mg) · Part A: Cohort 2: BNT331 5 mg · Part A: Cohort 3: BNT331 20 mg · Part B: Placebo (Combined for Cohorts 4 and 5) · Part B: Cohort 4: BNT331 5 mg · Part B: Cohort 5: BNT331 20 mg
Part A: Placebo (Combined for Cohorts 1, 2 and 3) · Part A: Cohort 1: BNT331 2 Milligram (mg) · Part A: Cohort 2: BNT331 5 mg · Part A: Cohort 3: BNT331 20 mg · Part B: Placebo (Combined for Cohorts 4 and 5) · Part B: Cohort 4: BNT331 5 mg · Part B: Cohort 5: BNT331 20 mg
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.